GILD Earnings

GILD reported its earnings on 2026-05-07, showcasing a revenue of 6.96B against an estimate of 6.89B, resulting in a 1.02% surprise. The EPS was 2.03, surpassing the expected 1.89 by 7.41%. The stock experienced a -2.04% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following GILD's earnings announcement on 2026-05-07, the stock price moved by -2.04% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, GILD's stock price tends to shift by an average of 0% in the 10 days leading up to earnings and 0.25% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate GILD's annual revenue to reach 7.49B, while the EPS is projected at 2.19. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between GILD's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, GILD's stock price typically moves by 0% in the 10 days before its earnings and 0.25% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of 2.19 and revenue of 7.49B.

The earnings call summary reflects positive sentiment, with robust financial performance, strategic product launches, and optimistic future guidance. Yeztugo's launch success and anticipated revenue growth, along with strong adherence and coverage, are promising. The Q&A section further supports this sentiment, highlighting management's confidence in their strategic initiatives, particularly in HIV and oncology segments. Despite some uncertainties in trials and adherence data, the overall outlook remains positive, driven by innovative products and strategic market expansion. The absence of significant negative news or guidance reinforces a positive stock price prediction.